## AMENDMENTS TO THE CLAIMS

This listing of claims will replace all prior versions, and listings, of claims in the present application.

### *Listing of Claims*

1. (currently amended) A compound of the structure:




(I)

or pharmaceutically acceptable salt, ester or salt of ester thereof;

wherein $R_1$ is hydrogen, aliphatic, heteroaliphatic, alicyclic or aryl;

$R_2$ ~~and~~ is methyl; $R_3$ ~~are each independently~~ is hydrogen~~,~~ or halogen~~, hydroxyl, protected hydroxyl, or an aliphatic, heteroaliphatic, alicyclic or aryl moiety; or~~

~~$R_1$ and $R_2$, when taken together, form a substituted or unsubstituted, saturated or unsaturated cyclic ring of 3 to 8 carbon atoms;~~

~~or $R_1$ and $R_3$, when taken together, form a substituted or unsubstituted, saturated or unsaturated cyclic ring of 3 to 8 carbon atoms~~;

$R_4$ is hydrogen or halogen;

$R_5$ is hydrogen or an oxygen protecting group;

$R_6$ is hydrogen, hydroxyl, or protected hydroxyl;

n is 0-2;

$R_7$~~, for each occurrence,~~ is ~~independently~~ hydrogen~~, hydroxyl, or protected hydroxyl~~;

$R_8$ is hydrogen, halogen, hydroxyl, protected hydroxyl~~,~~ or alkyloxy~~, or an aliphatic moiety optionally substituted with hydroxyl, protected hydroxyl, $SR_{12}$, or $NR_{12}R_{13}$~~;

$R_9$ is $NR_{12}R_{13}$;

wherein $R_{12}$ and $R_{13}$ are, independently for each occurrence, hydrogen, aliphatic, heteroaliphatic, alicyclic or aryl; or a protecting group, and each of $R_{12}$ and $R_{13}$ are

optionally further substituted with one or more occurrences of hydroxyl, protected hydroxyl, alkyloxy, amino, protected amino, alkylamino, aminoalkyl, or halogen,

$R_{10}$ is ~~hydrogen,~~ hydroxyl, protected hydroxyl, or amino~~, or protected amino~~;

$R_{11}$ is hydrogen~~, hydroxyl or protected hydroxyl~~;

X is ~~absent or is~~ O, NH, or N-alkyl~~, $CH_2$ or S~~;

Y is $CHR_{17}$, O, ~~C=O,~~ $CR_{17}$ or $NR_{17}$; and Z is $CHR_{18}$, ~~O,~~ C=O, or $CR_{18}$ ~~or $NR_{18}$~~, wherein each occurrence of $R_{17}$ and $R_{18}$ is ~~independently~~ hydrogen ~~or aliphatic~~, or $R_{17}$ and $R_{18}$ taken together is -O-, or $-CH_2-$ ~~or $NR_{19}$, wherein $R_{19}$ is hydrogen or $C_{1-6}$alkyl~~, and Y and Z are connected by a single or double bond.

2. (canceled)

3. (currently amended) A compound of the structure:




(I)

or pharmaceutically acceptable salt, ester or salt of ester thereof;

wherein: $R_1$ is hydrogen, straight or branched $C_{1-6}$alkyl, straight or branched $C_{1-6}$heteroalkyl, or aryl,

wherein the alkyl, heteroalkyl, and aryl groups may optionally be substituted with one or more occurrences of halogen, hydroxyl or protected hydroxyl;

$R_2$ is methyl; ~~and~~ $R_3$ ~~are each independently~~ is hydrogen~~,~~ or halogen~~, hydroxyl, protected hydroxyl, straight or branched $C_{1-6}$alkyl, straight or branched $C_{1-6}$heteroalkyl, or aryl,~~

~~wherein the alkyl, heteroalkyl, and aryl groups may optionally be substituted with one or more occurrences of halogen, hydroxyl or protected hydroxyl; or~~

~~$R_1$ and $R_2$, when taken together, form a saturated or unsaturated cyclic ring of 3 to 8 carbon atoms, optionally substituted with one or more occurrences of halogen; or~~

~~$R_1$ and $R_3$, when taken together, form a saturated or unsaturated cyclic ring of 3 to 8 carbon atoms, optionally substituted with one or more occurrences of halogen~~;

$R_4$ is hydrogen or halogen;

$R_5$ is hydrogen or a protecting group;

$R_6$ is hydrogen, hydroxyl, or protected hydroxyl;

n is 0-2;

$R_7$~~, for each occurrence,~~ is ~~independently~~ hydrogen~~, hydroxyl, or protected hydroxyl~~;

$R_8$ is hydrogen, halogen, hydroxyl, protected hydroxyl, or alkyloxy~~, or $C_{1-6}$alkyl optionally substituted with hydroxyl, protected hydroxyl, $SR_{12}$, or $NR_{12}R_{13}$~~;

$R_9$ is $NR_{12}R_{13}$;

wherein $R_{12}$ and $R_{13}$ are, independently for each occurrence, hydrogen, $C_{1-6}$alkyl, aryl, alkylaryl, or a protecting group, and each of $R_{12}$ and $R_{13}$ are optionally further substituted with one or more occurrences of hydroxyl, protected hydroxyl, alkyloxy, amino, protected amino, alkylamino, aminoalkyl, or halogen,

$R_{10}$ is ~~hydrogen,~~ hydroxyl, protected hydroxyl, or amino~~, or protected amino~~;

$R_{11}$ is hydrogen~~, hydroxyl or protected hydroxyl~~;

X is ~~absent or is~~ O, NH, or N-alkyl~~, $CH_2$ or S~~;

Y is $CHR_{17}$, O, ~~C=O,~~ $CR_{17}$ or $NR_{17}$; and Z is $CHR_{18}$, ~~O,~~ C=O, or $CR_{18}$~~ or $NR_{18}$~~, wherein each occurrence of $R_{17}$ and $R_{18}$ is ~~independently~~ hydrogen ~~or $C_{1-6}$alkyl,~~ or $R_{17}$ and $R_{18}$ taken together is -O-, or -$CH_2$~~ or $NR_{19}$, wherein $R_{19}$ is hydrogen or $C_{1-6}$alkyl~~, and Y and Z are connected by a single or double bond.

4. (original) The compound of claim 3, where X is oxygen and n is 1.

5. (original) The compound of claim 3, where $R_4$ is halogen.

6. (original) The compound of claim 3, where $R_4$ is fluorine.

7. (original) The compound of claim 3, where Y and Z together represent -CH=CH-

8. (original) The compound of claim 3, where Y and Z together represent trans -CH=CH-.

9. (currently amended) The compound of claim 3, wherein $R_1$ ~~and $R_2$ are each~~ is methyl and $R_3$ is hydrogen and the compound is of the structure:




wherein $R_4$-$R_{11}$, n, X, Y and Z are as defined in claim 3.

10. (original) The compound of claim 9, wherein X is oxygen and n is 1.

11. (original) The compound of claim 9, wherein $R_4$ is halogen.

12. (original) The compound of claim 9, wherein Y and Z together represent -CH=CH.

13. (original) The compound of claim 9, wherein X is oxygen, n is 1, $R_4$ is halogen and Y and Z together represent -CH=CH-.

14. (original) The compound of claim 12 or 13 wherein -CH=CH- is trans.

15. (canceled)

16. (canceled)

17. (currently amended) The compound of claim ~~15~~ 3, wherein $R_4$ is ~~halogen~~ hydrogen.

18. (currently amended) The compound of claim ~~15~~ 17, wherein Y and Z together represent -CH=CH-.

19. (currently amended) The compound of claim ~~15~~17, wherein $R_1$ ~~and $R_2$ are each~~ is methyl and $R_3$ is hydrogen.

20. (currently amended) The compound of claim ~~15~~17, wherein X is oxygen, n is 1, $R_1$ ~~and $R_2$ are each~~ is methyl, $R_3$ is hydrogen, ~~$R_4$ is halogen,~~ and Y and Z together represent -CH=CH-.

21. (original) The compound of claim 18 or 20, wherein -CH=CH- is trans.

22. (previously presented) The compound of claim 1, wherein the compound is of the structure:



or pharmaceutically acceptable salt, ester or salt of ester thereof.

23-36. (canceled)

37. (currently amended) A pharmaceutical composition comprising:

a compound of any one of claims 1, 3, 9 and ~~15~~17; or pharmaceutically acceptable salt, ester or salt of ester thereof; and a pharmaceutically acceptable carrier.

38. (original) The pharmaceutical composition of claim 37, wherein the compound is present in an amount effective to inhibit NF-κB activation.

39-42. (canceled)

43. (original) The pharmaceutical composition of claim 37, wherein the compound is present in an amount effective to have an anti-inflammatory effect.

44. (original) The pharmaceutical composition of claim 37, wherein the compound is present in an amount effective to treat psoriasis.

45. (original) The pharmaceutical composition of claim 37, wherein the compound is present in an amount effective to reduce skin photodamage.

46-65. (canceled)

66. (previously presented) The pharmaceutical composition of claim 37 wherein the compound has the structure:



,


,


,


,


,


,




,

or pharmaceutically acceptable salt, ester or salt of ester thereof.

67-83. (canceled)

84. (withdrawn, currently amended) A method for treating an inflammatory and/or autoimmune disorder or a disorder resulting from increased angiogenesis and/or cell proliferation comprising:

administering to a subject in need thereof a therapeutically effective amount of a compound of any one of claims 1, 3, ~~9~~ 131 and ~~15~~ 132; and a pharmaceutically acceptable carrier or diluent.

85. (withdrawn) The method of claim 84, wherein the method is for treating a disorder selected from the group consisting of rheumatoid arthritis, psoriasis, asthma, cancer, sepsis, inflammatory bowel disease, atopic dermatitis, Crohn's disease, and autoimmune disorders.

86. (withdrawn) The method of claim 84, wherein the method is for treating rheumatoid arthritis.

87. (withdrawn) The method of claim 84, wherein the method is for treating psoriasis.

88. (withdrawn) The method of claim 84, wherein the method is for treating asthma.

89-107. (canceled)

108. (withdrawn, previously presented) The method of claim 84, wherein the compound is of the structure:


,

,

,

,

,

,

,

or pharmaceutically acceptable salt, ester or salt of ester thereof.

109-118. (canceled)

119. (withdrawn, currently amended) A method for providing protection against UVB-induced photodamage to a subject, said method comprising:

administering to the subject in need thereof a composition comprising a compound of ~~the structure:~~




~~(I)~~

claim 1~~or pharmaceutically acceptable salt, ester or salt of ester thereof;~~

~~wherein $R_1$ is hydrogen, straight or branched $C_{1-6}$alkyl, straight or branched $C_{1-6}$heteroalkyl, or aryl,~~

~~wherein the alkyl, heteroalkyl, and aryl groups may optionally be substituted with one or more occurrences of halogen, hydroxyl or protected hydroxyl;~~

~~$R_2$ and $R_3$ are each independently hydrogen, halogen, hydroxyl, protected hydroxyl, straight or branched $C_{1-6}$alkyl, straight or branched $C_{1-6}$heteroalkyl, or aryl,~~

~~wherein the alkyl, heteroalkyl, and aryl groups may optionally be substituted with one or more occurrences of halogen, hydroxyl or protected hydroxyl; or~~

~~$R_1$ and $R_2$, when taken together, form a saturated or unsaturated cyclic ring of 3 to 8 carbon atoms, optionally substituted with one or more occurrences of halogen; or~~

~~$R_1$ and $R_3$, when taken together, form a saturated or unsaturated cyclic ring of 3 to 8 carbon atoms, optionally substituted with one or more occurrences of halogen;~~

~~$R_4$ is hydrogen or halogen;~~

~~$R_5$ is hydrogen or an oxygen protecting group;~~

~~$R_6$ is hydrogen, hydroxyl, or protected hydroxyl;~~

~~n is 0-2;~~

~~$R_7$, for each occurrence, is independently hydrogen, hydroxyl, or protected hydroxyl;~~

~~$R_8$ is hydrogen, halogen, hydroxyl, protected hydroxyl, alkyloxy, or $C_{1-6}$alkyl optionally substituted with hydroxyl, protected hydroxyl, $SR_{12}$, or $NR_{12}R_{13}$;~~

~~$R_9$ is $NR_{12}R_{13}$;~~

~~wherein $R_{12}$ and $R_{13}$ are, independently for each occurrence, hydrogen, $C_{1-6}$alkyl, aryl, alkylaryl, or a protecting group, and each of $R_{12}$ and $R_{13}$ are optionally further substituted with one or more occurrences of hydroxyl, protected hydroxyl, alkyloxy, amino, protected amino, alkylamino, aminoalkyl, or halogen,~~

~~$R_{10}$ is hydrogen, hydroxyl, protected hydroxyl, amino, or protected amino;~~

~~$R_{11}$ is hydrogen, hydroxyl or protected hydroxyl;~~

~~X is absent or is O, NH, N-alkyl, $CH_2$ or S;~~

~~Y is $CHR_{17}$, O, C=O, $CR_{17}$ or $NR_{17}$; and Z is $CHR_{18}$, O, C=O, $CR_{18}$ or $NR_{18}$, wherein each occurrence of $R_{17}$ and $R_{18}$ is independently hydrogen or $C_{1-6}$alkyl, or $R_{17}$ and $R_{18}$ taken together is O, $CH_2$ or $NR_{19}$, wherein $R_{19}$ is hydrogen or $C_{1-6}$alkyl, and Y and Z are connected by a single or double bond;~~ and

a pharmaceutically acceptable carrier or diluent.

120. (withdrawn) The method of claim 119, wherein in the step of administering, the composition is administered topically.

121. (withdrawn) The method of claim 119, wherein the photodamage is skin wrinkles.

122. (withdrawn) The method of claim 119, wherein the photodamage is a skin cancer.

123. (withdrawn, currently amended) A method for reducing the rate of restenosis, comprising:

inserting a stent into an obstructed blood vessel, the stent having a generally tubular structure, the surface of the structure being coated with (or otherwise adapted to release) a composition comprising a compound of ~~the structure:~~




~~(I)~~

claim 1~~or pharmaceutically acceptable salt, ester or salt of ester thereof;~~

~~wherein $R_1$ is hydrogen, straight or branched $C_{1-6}$alkyl, straight or branched $C_{1-6}$heteroalkyl, or aryl,~~

~~wherein the alkyl, heteroalkyl, and aryl groups may optionally be substituted with one or more occurrences of halogen, hydroxyl or protected hydroxyl;~~

~~$R_2$ and $R_3$ are each independently hydrogen, halogen, hydroxyl, protected hydroxyl, straight or branched $C_{1-6}$alkyl, straight or branched $C_{1-6}$heteroalkyl, or aryl,~~

~~wherein the alkyl, heteroalkyl, and aryl groups may optionally be substituted with one or more occurrences of halogen, hydroxyl or protected hydroxyl; or~~

~~$R_1$ and $R_2$, when taken together, may form a saturated or unsaturated cyclic ring of 3 to 8 carbon atoms, optionally substituted with one or more occurrences of halogen; or~~

~~$R_1$ and $R_3$, when taken together, form a saturated or unsaturated cyclic ring of 3 to 8 carbon atoms, optionally substituted with one or more occurrences of halogen;~~

~~$R_4$ is hydrogen or halogen;~~

~~$R_5$ is hydrogen or an oxygen protecting group;~~

~~$R_6$ is hydrogen, hydroxyl, or protected hydroxyl;~~

~~n is 0-2;~~

~~$R_7$, for each occurrence, is independently hydrogen, hydroxyl, or protected hydroxyl;~~

~~$R_8$ is hydrogen, halogen, hydroxyl, protected hydroxyl, alkyloxy, or $C_{1-6}$alkyl optionally substituted with hydroxyl, protected hydroxyl, $SR_{12}$, or $NR_{12}R_{13}$;~~

~~$R_9$ is $NR_{12}R_{13}$;~~

~~wherein $R_{12}$ and $R_{13}$ are, independently for each occurrence, hydrogen, $C_{1-6}$alkyl, aryl, alkylaryl, or a protecting group, and each of $R_{12}$ and $R_{13}$ are optionally further substituted with one or more occurrences of hydroxyl, protected hydroxyl, alkyloxy, amino, protected amino, alkylamino, aminoalkyl, or halogen,~~

~~$R_{10}$ is hydrogen, hydroxyl, protected hydroxyl, amino, or protected amino;~~

~~$R_{11}$ is hydrogen, hydroxyl or protected hydroxyl;~~

~~X is absent or is O, NH, N-alkyl, $CH_2$ or S;~~

~~Y is $CHR_{17}$, O, C=O, $CR_{17}$ or $NR_{17}$; and Z is $CHR_{18}$, O, C=O, $CR_{18}$ or $NR_{18}$, wherein each occurrence of $R_{17}$ and $R_{18}$ is independently hydrogen or $C_{1-6}$alkyl, or $R_{17}$ and $R_{18}$ taken together is =O, =$CH_2$ or =$NR_{19}$, wherein $R_{19}$ is hydrogen or $C_{1-6}$alkyl, and Y and Z are connected by a single or double bond;~~ and optionally a pharmaceutically acceptable carrier or diluent;

such that the obstruction is eliminated and the composition is delivered in amounts effective to prevent or reduce the rate of restenosis.

124. (withdrawn, currently amended) A method for expanding the lumen of a body passageway, comprising:

inserting a stent into the passageway, the stent having a generally tubular structure, the surface of the structure being coated with (or otherwise adapted to release) a composition comprising a compound of ~~the structure:~~




~~(I)~~

claim 1 ~~or pharmaceutically acceptable salt, ester or salt of ester thereof;~~

~~wherein $R_1$ is hydrogen, straight or branched $C_{1-6}$alkyl, straight or branched $C_{1-6}$heteroalkyl, or aryl,~~

~~wherein the alkyl, heteroalkyl, and aryl groups may optionally be substituted with one or more occurrences of halogen, hydroxyl or protected hydroxyl;~~

~~$R_2$ and $R_3$ are each independently hydrogen, halogen, hydroxyl, protected hydroxyl, straight or branched $C_{1-6}$alkyl, straight or branched $C_{1-6}$heteroalkyl, or aryl,~~

~~wherein the alkyl, heteroalkyl, and aryl groups may optionally be substituted with one or more occurrences of halogen, hydroxyl or protected hydroxyl; or~~

~~$R_1$ and $R_2$, when taken together, form a saturated or unsaturated cyclic ring of 3 to 8 carbon atoms, optionally substituted with one or more occurrences of halogen; or~~

~~$R_1$ and $R_3$, when taken together, form a saturated or unsaturated cyclic ring of 3 to 8 carbon atoms, optionally substituted with one or more occurrences of halogen;~~

~~$R_4$ is hydrogen or halogen;~~

~~$R_5$ is hydrogen or a protecting group;~~

~~$R_6$ is hydrogen, hydroxyl, or protected hydroxyl;~~

~~n is 0-2;~~

~~$R_7$, for each occurrence, is independently hydrogen, hydroxyl, or protected hydroxyl;~~

~~$R_8$ is hydrogen, halogen, hydroxyl, protected hydroxyl, alkyloxy, or $C_{1-6}$alkyl optionally substituted with hydroxyl, protected hydroxyl, $SR_{12}$, or $NR_{12}R_{13}$;~~

~~$R_9$ is $NR_{12}R_{13}$;~~

~~wherein $R_{12}$ and $R_{13}$ are, independently for each occurrence, hydrogen, $C_{1-6}$alkyl, aryl, alkylaryl, or a protecting group, and each of $R_{12}$ and $R_{13}$ are optionally further substituted with one or more occurrences of hydroxyl, protected hydroxyl, alkyloxy, amino, protected amino, alkylamino, aminoalkyl, or halogen,~~

~~$R_{10}$ is hydrogen, hydroxyl, protected hydroxyl, amino, or protected amino;~~

~~$R_{11}$ is hydrogen, hydroxyl or protected hydroxyl;~~

~~X is absent or is O, NH, N-alkyl, $CH_2$ or S;~~

~~Y is $CHR_{17}$, O, C=O, $CR_{17}$ or $NR_{17}$; and Z is $CHR_{18}$, O, C=O, $CR_{18}$ or $NR_{18}$, wherein each occurrence of $R_{17}$ and $R_{18}$ is independently hydrogen or $C_{1-6}$alkyl, or $R_{17}$ and $R_{18}$ taken together is =O, $=CH_2$ or $=NR_{19}$, wherein $R_{19}$ is hydrogen or $C_{1-6}$alkyl, and Y and Z are connected by a single or double bond;~~ and optionally a pharmaceutically acceptable carrier or diluent;

such that the passageway is expanded.

125. (withdrawn) The method of claim 124, wherein the lumen of a body passageway is expanded in order to eliminate a biliary, gastrointestinal, esophageal, tracheal/bronchial, urethral and/or vascular obstruction.

126. (withdrawn) The method of claim 125, wherein the lumen of a body passageway is expanded in order to eliminate a vascular obstruction.

127. (canceled)

128. (currently amended) A compound of claim ~~127~~21, wherein $R_{12}$ is methyl, ethyl, propyl, isopropyl or butyl, optionally substituted with one or more occurrences of hydroxyl or protected hydroxyl and wherein $R_{13}$ is hydrogen or $C_{1-6}$alkyl.

129. (previously presented) A compound of the formula:




or a pharmaceutically acceptable salt, ester or salt of ester thereof.

130. (previously presented) A compound of claim 129, wherein the compound is of the formula:



131. (previously presented) A compound of the formula:



or a pharmaceutically acceptable salt, ester or salt of ester thereof.

132. (previously presented) A compound of claim 131, wherein the compound is of the formula:



133. (withdrawn, new) The method of claim 119, said method comprising: administering to the subject in need thereof a composition comprising the compound of claims 3, 22, 131 and 132.

134. (withdrawn, new) The method of claim 123, said method comprising:

inserting a stent into an obstructed blood vessel, the stent having a generally tubular structure, the surface of the structure being coated with (or otherwise adapted to release) a composition comprising a compound of claims 3, 22, 131 and 132.

135. (withdrawn, new) The method of claim 124, said method comprising:
inserting a stent into the passageway, the stent having a generally tubular structure, the surface of the structure being coated with (or otherwise adapted to release) a composition comprising a compound of claims 3, 22, 131 and 132.